Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.43 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | EIF4E | P06730 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.35 |
| ▸ | KDM5A | P29375 | 1/20 | 0.34 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.33 |
| ▸ | FASN | P49327 | 1/20 | 0.33 |
| ▸ | RARA | P10276 | 1/20 | 0.32 |
| ▸ | RARB | P10826 | 1/20 | 0.32 |
| ▸ | RARG | P13631 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.32 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10030434 | 0.88 | PLAU (0.40) | MRGPRX4DRD1EGLN1HSP90AB1 | |
| SCHEMBL10030463 | 0.86 | HTR7 (0.38) | — | |
| SCHEMBL16502653 | 0.83 | SLC22A12 (0.46) | SLC22A12ALKMRGPRX4EIF4EKDM4C | |
| SCHEMBL9907622 | 0.75 | TDP1 (0.45) | SLC22A12ALKMRGPRX4EIF4EKDM4C | |
| SCHEMBL16502456 | 0.73 | SLC22A12 (0.56) | SLC22A12ALKMRGPRX4PLA2G2DRARA | |
| SCHEMBL10030420 | 0.73 | TTR (0.39) | KDM4CKDM5AKDM5BPLA2G2D | |
| SCHEMBL10030438 | 0.72 | CSNK2A2 (0.41) | PLA2G2D | |
| SCHEMBL10030431 | 0.72 | RAB9A (0.41) | SLC22A12PLA2G2D | |
| SCHEMBL10030447 | 0.72 | GRIN2D (0.43) | PLA2G2D | |
| SCHEMBL10030436 | 0.71 | TTR (0.40) | SLC22A12MRGPRX4PLA2G2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041036-A1 | SUBSTITUTED ACYLGUANIDINE DERIVATIVES (AS AMENDED) | ASTELLAS PHARMA INC. (JP) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041036-A1 | SUBSTITUTED ACYLGUANIDINE DERIVATIVES (AS AMENDED) | HTR5A, HTR2A, HTR1A | SLC22A12 1219/4885ALK 1827/4885MRGPRX4 2803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.